Work

An Appropriate Use of Accelerated Approval — Aducanumab for Alzheimer’s Disease

Year: 2021

Type: letter

Abstract: An Appropriate Use of Accelerated Approval The FDA decision to grant accelerated approval to aducanumab for Alzheimer’s disease fits squarely in the accelerated approval pathway, which was created ...

Source: New England Journal of Medicine

DOI: 10.1056/nejmc2111960

Authors: Billy Dunn, Peter Stein, Robert Temple, Patrizia Cavazzoni

Institution: United States Food and Drug Administration

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Cellular and Molecular Neuroscience

Field: Neuroscience

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3185318240

Cites: 2

Cited by: 42

Related to: 10